



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Greta Varchi,
✉ greta.varchi@isof.cnr.it
Francesca Moret,
✉ francesca.moret@unipd.it

RECEIVED 04 June 2024
ACCEPTED 05 June 2024
PUBLISHED 18 June 2024

CITATION
Tubertini M, Menilli L, Milani C, Martini C,
Navacchia ML, Nugnes M, Bartolini M, Naldi M,
Tedesco D, Martella E, Guerrini A, Ferroni C,
Moret F and Varchi G (2024), Corrigendum:
HSA-nanobinders crafted from bioresponsive
prodrugs for combined cancer
chemoimmunotherapy—an *in vitro* exploration.
Front. Chem. 12:1443822.
doi: 10.3389/fchem.2024.1443822

COPYRIGHT
© 2024 Tubertini, Menilli, Milani, Martini,
Navacchia, Nugnes, Bartolini, Naldi, Tedesco,
Martella, Guerrini, Ferroni, Moret and Varchi.
This is an open-access article distributed under
the terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy—an *in vitro* exploration

Matilde Tubertini^{1,2}, Luca Menilli³, Celeste Milani⁴,
Cecilia Martini¹, Maria Luisa Navacchia¹, Marta Nugnes⁵,
Manuela Bartolini⁵, Marina Naldi⁵, Daniele Tedesco¹,
Elisa Martella¹, Andrea Guerrini¹, Claudia Ferroni¹,
Francesca Moret^{4*} and Greta Varchi^{1*}

¹Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Bologna, Italy, ²Department of Science and High Technology, University of Insubria, Como, Italy, ³Pharmacy Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy, ⁴Department of Biology (DiBio), University of Padova, Padua, Italy, ⁵Department of Pharmacy and Biotechnology (FaBIT), University of Bologna, Bologna, Italy

KEYWORDS

prodrugs, chemotherapy, IDO1 inhibition, endogenous human serum albumin, carrier-free nanoparticles, truncated evans blue, triple-negative breast cancer

A Corrigendum on

HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy—an *in vitro* exploration

by Tubertini M, Menilli L, Milani C, Martini C, Navacchia ML, Nugnes M, Bartolini M, Naldi M, Tedesco D, Martella E, Guerrini A, Ferroni C, Moret F and Varchi G (2024). *Front. Chem.* 12:1378233. doi: 10.3389/fchem.2024.1378233

In the published article, there was an error in the **Affiliation**. Matilde Tubertini's second affiliation was missing. The correct affiliations appear above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.